3 Budding Drug Superstars in This Big Pharma's Future
It's safe to say that investors have been happy with Bristol-Myers Squibb in 2013. This big pharma powerhouse has jumped to gains of more than 55% on the year, outpacing its health care rivals by a landslide. Bristol has done a good job of evading the worst of the patent cliff in its climb, and one look to the future shows that this pharmaceutical giant could see a few drugs with huge potential deliver even bigger gains.
From oncology to rheumatoid arthritis treatments, Bristol's pipeline is stacked with capable drug candidates undergoing clinical trials. Bristol launched one of its stars recently -- much-hyped blood thinner Eliquis, which Bristol co-developed alongside Pfizer -- after it received FDA approval late last year. Eliquis hasn't gotten off to a fast start, but it's bristling with potential nonetheless.
Which drugs can revolutionize Bristol's future and keep this big pharma giant at the top of the pack? Find out in the video below, where Fool contributor Dan Carroll reviews three drugs -- including Eliquis -- that could establish Bristol's coming years as some of the best in the health care sector and reward investors with handsome long-term gains.
The best dividend stocks for your money
Big pharma stocks like Bristol have been a longtime favorite of many dividend investors. It's simple, really: Dividend stocks can make you rich. While they don't garner the notoriety of high-flying growth stocks, they're also less likely to crash and burn. And over the long term, the compounding effect of the quarterly payouts, as well as their growth, adds up faster than most investors imagine. With this in mind, our analysts sat down to identify the absolute best of the best when it comes to rock-solid dividend stocks, drawing up a list in this free report of nine that fit the bill. To discover the identities of these companies before the rest of the market catches on, you can download this valuable free report by simply clicking here now.
The article 3 Budding Drug Superstars in This Big Pharma's Future originally appeared on Fool.com.
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
